BIOFILCHEM vs SUPRIYA: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Supriya Lifescience Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Supriya Lifescience Limited is the larger company by market capitalisation. Supriya Lifescience Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Supriya Lifescience Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 0 of 11 scored metrics and SUPRIYA on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUPRIYA is the larger company
₹6,689 Cr vs ₹53 Cr
EPS
SUPRIYA has higher earnings per share
₹25.94 vs ₹1.71
Dividend Yield
SUPRIYA has a higher dividend yield
0.11% vs 0%
Revenue Growth (TTM YoY)
SUPRIYA has faster revenue growth
50.2% vs -9.3%
EPS Growth (TTM YoY)
SUPRIYA has faster EPS growth
46.7% vs 10.8%
Qtr Sales Growth
SUPRIYA has stronger quarterly sales growth
50.2% vs -9.34%
Qtr Profit Growth
SUPRIYA has stronger quarterly profit growth
47.3% vs 5%
ROE
SUPRIYA has a higher ROE
19.1% vs 13.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMSUPRIYA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMSUPRIYA
Live Price₹32.64₹830.1
Day Change-0.55%-1.75%
Volume4,04892,852
52-Week High₹46.34₹1,085
52-Week Low₹25.6₹545.5
Distance from 52W High-29.56%-23.49%

Valuation

MetricBIOFILCHEMSUPRIYA
Market Cap₹53 Cr₹6,689 Cr
P/E Ratio31.98x
P/B Ratio5.58x
EPS₹1.71₹25.94
Book Value₹13.21₹148.77
Dividend Yield0%0.11%

Growth

MetricBIOFILCHEMSUPRIYA
Revenue Growth (TTM YoY)-9.3%50.2%
EPS Growth (TTM YoY)10.8%46.7%
Qtr Sales Growth-9.34%50.2%
Qtr Profit Growth5%47.3%

Profitability & Leverage

MetricBIOFILCHEMSUPRIYA
ROE13.8%19.1%
ROCE15.8%25.1%
Net Margin9.81%25.26%
Operating Margin2.29%35.5%
Debt to Equity0.14x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMSUPRIYA
Promoter Holding46.79%68.3%
FII Holding0%6.19% 1.03 pp
DII Holding0.08%5.3% 0.4 pp
Public Holding53.13%20.21% 0.63 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Supriya Lifescience Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.